EGFR and head and neck squamous cell carcinoma: Building on these findings, a Phase 2 study in heavily pretreated EGFR-positive HNSCC patients (62 total) reported a confirmed ORR of 43% and a DCR of 86% at the 2.3 mg/kg dose level, with a mPFS of 4.2 months and a median overall survival (OS) of 11.3 months [115].